Targeted therapy in breast cancer (Homo sapiens)
From WikiPathways
Description
"Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit HER signaling by binding to the intracellular tyrosine kinase domain of the Her family members. EGFR epidermal growth factor receptor, HER human epidermal growth factor receptor, MEK MAP kinase kinase, ERK MAP kinase, PI3K phosphoinositide 3-kinases (adapted from “HER2 Signaling Pathway”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates)". Source: Figure F1, https://pmc.ncbi.nlm.nih.gov/articles/PMC9281252/. Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC9281252__12032_2022_1749_Fig1_HTML.html.
Quality Tags
Ontology Terms
Saving...Bibliography
- Demir Cetinkaya B, Biray Avci C; ''Molecular perspective on targeted therapy in breast cancer: a review of current status.''; Med Oncol, 2022 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
| Name | Type | Database reference | Comment |
|---|---|---|---|
| HRAS | GeneProduct | ENSG00000174775 (Ensembl)  | |
| KRAS | GeneProduct | ENSG00000133703 (Ensembl) | |
| MAP2K1 | GeneProduct | ENSG00000107356 (Ensembl) | |
| MAP2K2 | GeneProduct | ENSG00000101418 (Ensembl) | |
| MAP2K3 | GeneProduct | ENSG00000107958 (Ensembl) | |
| MAP2K4 | GeneProduct | ENSG00000115669 (Ensembl) | |
| MAP2K5 | GeneProduct | ENSG00000138015 (Ensembl) | |
| MAP2K6 | GeneProduct | ENSG00000129652 (Ensembl) | |
| MAP2K7 | GeneProduct | ENSG00000118907 (Ensembl) | |
| NRAS | GeneProduct | ENSG00000213281 (Ensembl) | |
| RAF1 | GeneProduct | ENSG00000132155 (Ensembl) |
Annotated Interactions
No annotated interactions
